ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma

Sun, Hao; Liu, Si-Yang; Zhou, Jia-Ying; Xu, Jin-Tian; Zhang, Huang-Kai; Yan, Hong-Hong; Huan, Jiao-Jiao; Dai, Ping-Ping; Xu, Chong-Rui; Su, Jian; Guan, Yan-Fang; Yi, Xin; Yu, Rong-Shan; Zhong, Wen-Zhao; Wu, Yi-Long*厦门大学
EBioMedicine2020-10DOI: 10.1016/j.ebiom.2020.102990
89被引10阅读
引用收藏
分享

摘要

Background: Although TP53 co-mutation with KRAS/ATM/EGFR/STK11 have been proved to have predictive value for response to immune checkpoint inhibitors (ICIs), not all TP53 mutations are equal in this context. As the main part of TP53 mutant types, Missense and Nonsense alternations in TP53 as independent factors to predict the response to ICIs within Lung Adenocarcinoma (LUAD) patients have not yet been reported. @@@ Methods: An integrated analysis based on multiple-dimensional data types including genomic, transcriptomic, proteomic and clinical data from published lung adenocarcinoma data and local database of LUAD taking immune checkpoint inhibitors. Gene set enrichment analysis (GSEA) was used to determine potentially relevant gene expression signatures between specific subgroups. Single-sample GSEA (GSVA) is conducted to calculate the score for enrichment of a set of genes regulating DNA damage repair (DDR) pathway. @@@ Findings: The TP53-missense-mutation group showed increased PD-L1 (CD274) level and enriched IFN-g signatures compared with the TP53-wild-type subgroup, but no differences were noted in patients with nonsense-mutant vs wild-type p53. Furthermore, a group of suppressor Immune cells like M2 Macrophage and Neutrophils are found enriched in nonsense group. On the other-side, both TP53 missense and nonsense mutations are associated with elevated TMB and neoantigen levels and contribute equally to DNA damage repair deficiency. The distribution regarding to multi-dimensional factors determining the efficacy of ICIs finally transformed into diverse clinical benefits for LUAD. TP53 missense but not-nonsense Mutants are associated with better clinical benefits taking antiPD-1/1L. However, all such TP53 subgroups responds well to nivolumab (antiPD-L1) plus ipilimumab (antiCTLA-4) therapy. @@@ Interpretation: Our study demonstrated that not all TP53 mutations are equal in predicting efficacy in patients with LUAD treated with ICIs. Multi-center data showed that TP53 missense and nonsense mutations were significantly different in terms of associations with PD-L1 expression, IFN-g signatures and TME composition. Special attention should be paid to potential TP53 mutation heterogeneity when evaluating TP53 status as biomarker for ICIs. @@@ Funding: The study was supported by Key Lab System Project of Guangdong Science and Technology Department-Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer (Grant No.

学科与关键词

关键词
TP53Lung adenocarcinomaImmunotherapySubtypes
相关
加载中…
  • Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu, Chengde; Rao, Xiang; Lin, WeiCancer Med, 2021, 10(3): 806-823.
  • Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors
    Wen, Yang; Lin, Anqi; Zhu, Weiliang; Wei, Ting; Luo, Peng*; Guo, Linlang*; Zhang, Jian*Frontiers in Pharmacology, 2021, 12: 645862.被引 4
  • Genomic correlates of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients
    Li, Kang; Liu, Jun; Wu, Lin; Xiao, Yajie; Li, Jia; Du, Haijian; Zhao, Zhikun; Sun, Chao; Zhao, Yongtian; Yang, Jie; Wu, Dongfang; Zhao, Zhuxiang*; Chen, Bolin*Cancer Cell International, 2022, 22(1): 138.被引 7
查看全部 →

发表信息

论文状态
公开发表
期刊
EBioMedicine
发表日期
2020-10
卷期
第 60 卷
页码
102990
DOI
10.1016/j.ebiom.2020.102990
期刊收录
NSL.SCIE
期刊等级
1区
成果收录
SCIE
资助标注
Key Lab System Project of Guangdong Science and Technology Department - Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer [2017B030314120]

作者

  • S

    Sun, Hao (第一作者)

  • L

    Liu, Si-Yang

查看全部 15 位作者收起作者
  • Z

    Zhou, Jia-Ying

  • X

    Xu, Jin-Tian

  • Z

    Zhang, Huang-Kai

  • Y

    Yan, Hong-Hong

  • H

    Huan, Jiao-Jiao

  • D

    Dai, Ping-Ping

  • X

    Xu, Chong-Rui

  • S

    Su, Jian

  • G

    Guan, Yan-Fang

  • Y

    Yi, Xin

  • Y

    Yu, Rong-Shan

    xiamen univ

  • Z

    Zhong, Wen-Zhao

  • W

    Wu, Yi-Long (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417